Recent Development of Novel HDAC6 Isoform-selective Inhibitors

Title:Recent Development of Novel HDAC6 Isoform-selective Inhibitors

Volume: 28 Issue: 21

Author(s): Yunpeng Zhao, Tao Liang, Xuben Hou*Hao Fang*

Affiliation:

• Department of Medicinal Chemistry, Key Laboratory of Chemical Biology, School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, 44, Wenhuaxi Road, Jinan, Shandong, 250012,China

• Department of Medicinal Chemistry, Key Laboratory of Chemical Biology, School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, 44, Wenhuaxi Road, Jinan, Shandong, 250012,China

Keywords: post-transcription modification, HDAC6, structure, cancer, selective inhibitor, histone deacetylation.

Abstract: As an important post-transcription modification, histone deacetylation plays significant roles in chromatin remodeling and gene expression. The aberrant modification of histone deacetylation leads to various diseases. As a critical member of histone deacetylase (HDAC), HDAC6 serves as a key modulator in many physiological processes. Abnormal expression of HDAC6 gives rise to cancer, neurodegeneration and other diseases. Here, we have reviewed recent advances in physiological, protein structure and development of HDAC6 selective inhibitors.

Cite this article as:

Zhao Yunpeng , Liang Tao, Hou Xuben*, Fang Hao *, Recent Development of Novel HDAC6 Isoform-selective Inhibitors, Current Medicinal Chemistry 2021; 28 (21) . https://dx.doi.org/10.2174/0929867327666201111142653